目的对比单节段颈前路减压植骨融合内固定(ACDF)术后留置引流与否的安全性和临床结果。方法将2017年1月至2018年6月行单节段ACDF术且符合选择标准的100例患者进行前瞻性研究,随机分为引流组(术后给予常压引流,50例)和非引流组(术后不留...目的对比单节段颈前路减压植骨融合内固定(ACDF)术后留置引流与否的安全性和临床结果。方法将2017年1月至2018年6月行单节段ACDF术且符合选择标准的100例患者进行前瞻性研究,随机分为引流组(术后给予常压引流,50例)和非引流组(术后不留置引流,50例)。两组采用相同的术前准备、手术技术和术后处理,比较两组患者的各项围手术期指标,手术前后日本骨科协会(JOA)、视觉模拟评分法(VAS)、颈部功能障碍指数(NDI)评分和并发症发生情况。结果两组患者术后1 a JOA评分较术前提高(P<0.05),VAS、NDI评分均较术前降低(P<0.05);两组患者术前和术后随访时JOA、VAS、NDI评分比较,差异无统计学意义(均P>0.05)。非引流组住院时间比引流组短(P<0.05)。两组术后并发症发生率比较,差异无统计学意义(P>0.05)。结论单节段颈前路减压内固定术后留置引流与不留置引流的安全性和临床疗效一致,且不留置引流可以缩短患者住院时间。展开更多
OBJECTIVE To investigate the effects of T-006(tetramethylpyrazine derivative)in promotingα-Synuclein(α-Syn)degradation and evaluated the neuroprotective effects in cellular and animalα-Syn model of Parkinson diseas...OBJECTIVE To investigate the effects of T-006(tetramethylpyrazine derivative)in promotingα-Synuclein(α-Syn)degradation and evaluated the neuroprotective effects in cellular and animalα-Syn model of Parkinson disease(PD).METHODS The inducible PC12 cells overexpressingα-syn and the homozygous transgenic(Tg)mice expressing A53T humanα-syn were used to evaluate the neuroprotective effects of T-006.For cellular study,MTT,Western blotting,proteasomal activity assay and qRT-PCR were applied to analyze the pharmacological effects and underlying mecha⁃nisms.The gene knock-down and overexpression approaches were used to dissect the molecular signaling pathways.For animal study,ten-month-old homozygousα-Syn Tg mice were treated with T-006(3 mg·kg-1)daily by gavage for four weeks.The Western blotting,immunohistochemistry and behavioral tests were applied to determine the neuropatho⁃logical changes.RESULTS T-006 promoted the degradation of WT and mutantα-Syn in PC12α-Syn inducible cells via an ubiquitin-proteasome system(UPS)dependent and autophagy-lysosome pathway independent manner.The mecha⁃nism of action involved the upregulation of 20S proteasome subunit LMP7 expression,which leads to activation of the chymotrypsin-like proteasomal activity for protein degradation.Mechanistically,we demonstrated that T-006 activated PKA/Akt/mTOR pathway upstream for LMP 7 up-regulation and UPS activation.Finally,we illustrated that T-006 promoted both Triton-soluble and-insoluble forms ofα-syn and protected againstα-Syn-induced neurotoxicity in A53Tα-Syn Tg mice.CONCLUSION T-006 is a potent UPS activator which promotes the degradation of pathogenic proteinα-Syn in cellular and animal PD models.Our study thus high-lights the therapeutic potential of small molecular UPS activator like T-006 in the treatment of PD and related conditions.展开更多
OBJECTIVE Amyotrophic lateral sclerosis(ALS)is a fatal neurodegenerative dis⁃ease characterized by progressive loss of upper and lower motor neurons that results in skeletal muscle atrophy,weakness and paralysis.Oxida...OBJECTIVE Amyotrophic lateral sclerosis(ALS)is a fatal neurodegenerative dis⁃ease characterized by progressive loss of upper and lower motor neurons that results in skeletal muscle atrophy,weakness and paralysis.Oxida⁃tive stress plays a key role in the pathogenesis of ALS,including familial forms of the disease arising from mutation of the gene coding for superoxide dismutase 1(SOD1).Moreover,although the pathogenesis of ALS is unclear,the abnormal accumulation of TAR DNA-binding pro⁃tein of 43 ku(TDP-43)is a pathological feature that exists in almost all patients.Thus far,there is no drug that can cure ALS/FTLD.Tetramethyl⁃pyrazine nitrone(TBN)is a derivative of tetra⁃methylapyrazine,derived from the traditional Chinese medicine Ligusticum chuanxiong,which has been widely proven to have therapeutic effects on models of various neurodegenerative diseases.TBN is currently under clinical investi⁃gation for several indications including a phaseⅡtrial of ALS.Here,we explored the therapeutic effect of TBN in the SOD1G93A and TDP-43M337V ALS mouse model.METHODS In the SOD1G93A transgenic mouse model,TBN was administered to mice by intraperitoneal or intragastric injection after the onset of motor deficits.At the same time,we unilaterally and bilaterally injected the TDP-43M337V virus into the striatum of the WT mouse,and gave the TBN treatment after the mice developed a phenotype.After administering these two models for a period of time,we con⁃ducted behavioral tests,including rotarod test,balance beam test,climbing pole test,etc,to evaluate the efficacy of TBN on SOD1G93A and TDP-43M337V models.Furthermore,we explored the possible mechanism of action of TBN in the treatment of ALS through Western blotting and immunohistochemistry/immunofluorescence staining analysis.RESULTS In the SOD1G93A transgenic mouse model,TBN slowed the pro⁃gression of motor neuron disease as evidenced by improved motor performance,reduced spinal motor neuron loss and the associated glial response,and decreased skeletal muscle fiber denervation and fibrosis.TBN treatment activated mitochondrial antioxidant activity through the PGC-1α/Nrf2/HO-1 pathway and decreased the expression of human SOD1.What′s more,in the TDP-43M337V mice model,the results showed that in mice with unilateral injection of TDP-43M337V,TBN improved motor deficits and cognitive im⁃pairment in the early stages of disease progres⁃sion.In mice with bilateral injection of TDP-43M337V into the striatum,TBN not only improved motor function but also prolonged survival rate.Moreover,we show that its therapeutic effect may be through activation of the Akt/mTOR/GSK-3βand AMPK/PGC-1α/Nrf2 signaling pathways.In summary,TBN is a promising agent for the treat⁃ment of ALS/FTLD.CONCLUSION TBN has shown good efficacy in both SOD1 and TDP-43 ALS-related models,and it may act by activating the AMPK/PGC-1α/Nrf2 signaling pathway,which shows some light for the development of ALS therapeutic drugs.展开更多
文摘目的对比单节段颈前路减压植骨融合内固定(ACDF)术后留置引流与否的安全性和临床结果。方法将2017年1月至2018年6月行单节段ACDF术且符合选择标准的100例患者进行前瞻性研究,随机分为引流组(术后给予常压引流,50例)和非引流组(术后不留置引流,50例)。两组采用相同的术前准备、手术技术和术后处理,比较两组患者的各项围手术期指标,手术前后日本骨科协会(JOA)、视觉模拟评分法(VAS)、颈部功能障碍指数(NDI)评分和并发症发生情况。结果两组患者术后1 a JOA评分较术前提高(P<0.05),VAS、NDI评分均较术前降低(P<0.05);两组患者术前和术后随访时JOA、VAS、NDI评分比较,差异无统计学意义(均P>0.05)。非引流组住院时间比引流组短(P<0.05)。两组术后并发症发生率比较,差异无统计学意义(P>0.05)。结论单节段颈前路减压内固定术后留置引流与不留置引流的安全性和临床疗效一致,且不留置引流可以缩短患者住院时间。
基金Science and Technology Development Fund(FDCT)of Macao SAR(069/2015/A2134/2014/A3+4 种基金062-2017-AIR)Research Committee,University of Macao(MYRG2015-00182-ICMS-QRCMMYRG2015-00214-ICMSQRCMMYRG139(Y1-L4)-ICMS12-LMYand MYRG2016-00129-ICMS-QRCM)
文摘OBJECTIVE To investigate the effects of T-006(tetramethylpyrazine derivative)in promotingα-Synuclein(α-Syn)degradation and evaluated the neuroprotective effects in cellular and animalα-Syn model of Parkinson disease(PD).METHODS The inducible PC12 cells overexpressingα-syn and the homozygous transgenic(Tg)mice expressing A53T humanα-syn were used to evaluate the neuroprotective effects of T-006.For cellular study,MTT,Western blotting,proteasomal activity assay and qRT-PCR were applied to analyze the pharmacological effects and underlying mecha⁃nisms.The gene knock-down and overexpression approaches were used to dissect the molecular signaling pathways.For animal study,ten-month-old homozygousα-Syn Tg mice were treated with T-006(3 mg·kg-1)daily by gavage for four weeks.The Western blotting,immunohistochemistry and behavioral tests were applied to determine the neuropatho⁃logical changes.RESULTS T-006 promoted the degradation of WT and mutantα-Syn in PC12α-Syn inducible cells via an ubiquitin-proteasome system(UPS)dependent and autophagy-lysosome pathway independent manner.The mecha⁃nism of action involved the upregulation of 20S proteasome subunit LMP7 expression,which leads to activation of the chymotrypsin-like proteasomal activity for protein degradation.Mechanistically,we demonstrated that T-006 activated PKA/Akt/mTOR pathway upstream for LMP 7 up-regulation and UPS activation.Finally,we illustrated that T-006 promoted both Triton-soluble and-insoluble forms ofα-syn and protected againstα-Syn-induced neurotoxicity in A53Tα-Syn Tg mice.CONCLUSION T-006 is a potent UPS activator which promotes the degradation of pathogenic proteinα-Syn in cellular and animal PD models.Our study thus high-lights the therapeutic potential of small molecular UPS activator like T-006 in the treatment of PD and related conditions.
文摘OBJECTIVE Amyotrophic lateral sclerosis(ALS)is a fatal neurodegenerative dis⁃ease characterized by progressive loss of upper and lower motor neurons that results in skeletal muscle atrophy,weakness and paralysis.Oxida⁃tive stress plays a key role in the pathogenesis of ALS,including familial forms of the disease arising from mutation of the gene coding for superoxide dismutase 1(SOD1).Moreover,although the pathogenesis of ALS is unclear,the abnormal accumulation of TAR DNA-binding pro⁃tein of 43 ku(TDP-43)is a pathological feature that exists in almost all patients.Thus far,there is no drug that can cure ALS/FTLD.Tetramethyl⁃pyrazine nitrone(TBN)is a derivative of tetra⁃methylapyrazine,derived from the traditional Chinese medicine Ligusticum chuanxiong,which has been widely proven to have therapeutic effects on models of various neurodegenerative diseases.TBN is currently under clinical investi⁃gation for several indications including a phaseⅡtrial of ALS.Here,we explored the therapeutic effect of TBN in the SOD1G93A and TDP-43M337V ALS mouse model.METHODS In the SOD1G93A transgenic mouse model,TBN was administered to mice by intraperitoneal or intragastric injection after the onset of motor deficits.At the same time,we unilaterally and bilaterally injected the TDP-43M337V virus into the striatum of the WT mouse,and gave the TBN treatment after the mice developed a phenotype.After administering these two models for a period of time,we con⁃ducted behavioral tests,including rotarod test,balance beam test,climbing pole test,etc,to evaluate the efficacy of TBN on SOD1G93A and TDP-43M337V models.Furthermore,we explored the possible mechanism of action of TBN in the treatment of ALS through Western blotting and immunohistochemistry/immunofluorescence staining analysis.RESULTS In the SOD1G93A transgenic mouse model,TBN slowed the pro⁃gression of motor neuron disease as evidenced by improved motor performance,reduced spinal motor neuron loss and the associated glial response,and decreased skeletal muscle fiber denervation and fibrosis.TBN treatment activated mitochondrial antioxidant activity through the PGC-1α/Nrf2/HO-1 pathway and decreased the expression of human SOD1.What′s more,in the TDP-43M337V mice model,the results showed that in mice with unilateral injection of TDP-43M337V,TBN improved motor deficits and cognitive im⁃pairment in the early stages of disease progres⁃sion.In mice with bilateral injection of TDP-43M337V into the striatum,TBN not only improved motor function but also prolonged survival rate.Moreover,we show that its therapeutic effect may be through activation of the Akt/mTOR/GSK-3βand AMPK/PGC-1α/Nrf2 signaling pathways.In summary,TBN is a promising agent for the treat⁃ment of ALS/FTLD.CONCLUSION TBN has shown good efficacy in both SOD1 and TDP-43 ALS-related models,and it may act by activating the AMPK/PGC-1α/Nrf2 signaling pathway,which shows some light for the development of ALS therapeutic drugs.